tiprankstipranks
Indaptus Therapeutics expects cash to support activities through 3Q24
PremiumThe FlyIndaptus Therapeutics expects cash to support activities through 3Q24
1M ago
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
PremiumThe Fly
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
1M ago
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
PremiumPress Releases
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
2M ago
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
PremiumPress ReleasesEuropean Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
4M ago
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6M ago
Indaptus Therapeutics announces interim data from Phase 1 INDP-D101 trial
PremiumThe Fly
Indaptus Therapeutics announces interim data from Phase 1 INDP-D101 trial
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100